O. C. Burghuber (Vienna, Austria), H. Olschewski (Giessen, Germany)
Single centre experience with endothelin receptor blockade in pulmonary hypertension
I. J. Armstrong, C. A. Elliot, R. Barraclough, C. Billings, J. Waterhouse, L. O‘Toole, E. A. Taylor, D. G. Kiely (Sheffield, United Kingdom)
|   |
The incremental shuttle walking test safely assesses exercise capacity in pulmonary hypertension
C. Billings, J. Waterhouse, I. J. Armstrong, C. A. Elliot, J. Phillips, I. Smith, A. Appleton, T. Jones, A. Proctor, D. G. Kiely (Sheffield, United Kingdom)
| |
Incremental shuttle walking test distance predicts poor prognosis in pulmonary hypertension
C. A. Elliot, I. J. Armstrong, C. Billings, J. Waterhouse, N. Hamilton, D. G. Kiely (Sheffield, United Kingdom)
| |
Use of iloprost in early pregancy in pulmonary hypertension
C. A. Elliot, P. Stewart, V. Webster, G. Mills, D. Shepherd, S. Hutchinson, D. Breen, E. Howarth, R. Vaughan, R. Lawson, I. J. Armstrong, D. G. Kiely (Sheffield, United Kingdom)
| |
Successful pregnancy outcome in patients with pulmonary arterial hypertension receiving prostayclin therapy
D. Bendayan, M. Hod, A. Sagie, D. Shitrit, M. Kramer (Petah-Tikvah, Petah-Tikva, Petah- Tikva, Israel)
| |
Renin-angiotensin-aldosterone system activation in different vasculature areas in primary pulmonary hypertension
T. V. Martynyuk, N. A. Mironova, I. Y. Chazova (Moscow, Russia)
| |
Correlation between echo and catheterization studies in a measurement of pulmonary arterial pressure in Kyrgyz highlanders
B. K. Kojonazarov, B. J. Imanov, T. A. Amatov, T. M. Sooronbaev, M. K. Dadabaev, M. M. Mirrakhimov, N. W. Morrell, M. R. Wilkins, A. A. Aldashev (Bishkek, Kyrgyzstan; Cambridge, London, United Kingdom)
| |
Transition from nebulised iloprost therapy to subcutaneous treprostinil
I. Otero, M. Blanco-Aparicio, C. Montero, G. Rodriguez trigo, H. Verea Hernando (Coruña, Spain)
| |